Oral micro-nano CRISPR / Cas9 editing system and construction method and application thereof

Through a bilayer structure-coated micro-Nano CRISPR/Cas9 editing system, the CRISPR/Cas9 gene editing system was solved in the treatment of inflammatory bowel disease using disulfide crosslinking agents, bacterial outer membrane vesicles and calcium alginate coating. The delivery challenge has achieved effective gene editing and intestinal microbial improvements, providing novel treatment options for inflammatory bowel disease.

CN118956865APending Publication Date: 2024-11-15SHENYANG PHARMA UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411014088.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing CRISPR/Cas9 gene editing technology faces the challenge of effective and accurate delivery of larger RNP complexes in the treatment of inflammatory bowel disease, especially the immunogenicity and hepatotoxicity of viral vectors, and traditional drug treatments exist. Adverse reactions.

Method used

Design a bilayer structure-coated micro-nano CRISPR/Cas9 editing system to form RNP nanoclusters using disulfide crosslinking agents, and remove outer membrane vesicles and alginic acid from E. coli Nissle 1917 Calcium microspheres are coated to achieve oral delivery, protect the contents into colon tissue and release them in an inflammatory environment for gene editing.

Benefits of technology

The CRISPR/Cas9 gene editing system is effectively targeted to colon tissue, improve the intestinal microbiota, reduce the production of reactive oxygen species in inflammatory cells, improve gene editing efficiency, and provide a new gene therapy plan for inflammatory bowel disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956865A_ABST
    Figure CN118956865A_ABST
Patent Text Reader

Abstract

The invention discloses an oral micro-nano CRISPR / Cas9 editing system as well as a construction method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: taking Cas9 / sgRNA RNP as a gene editing medicine, and crosslinking the Cas9 / sgRNA RNP by utilizing a disulfide crosslinking agent to form RNP nanoclusters; the preparation method comprises the following steps: firstly, preparing RNP nanoclusters, firstly, carrying out primary coating on the RNP nanoclusters by using lipopolysaccharide-removed bacterial outer membrane vesicles (dOMVs) from E.coli Nissle 1917 (EcN), and finally, carrying out calcium alginate coating on the outer layers of the RNP nanoclusters to prepare a double-layer coated gene delivery system, and carrying out double-layer coating on calcium alginate and the bacterial outer membrane vesicles to realize efficient co-loading and synchronous delivery of a CRISPR / Cas9 editing system. The preparation process is simple, the particle size of the preparation is uniform, and targeting to colon tissue is facilitated; the drug loading capacity is high; and the safety is good. According to the oral micro-nano CRISPR / Cas9 editing system disclosed by the invention, the in-vivo gene editing and anti-inflammatory effects of the Cas9 / sgRNA RNP can be remarkably improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology and relates to the construction of an oral micro-nano CRISPR / Cas9 editing system, and specifically to the construction of a double-layer structure-coated CRISPR / Cas9 editing system and its application in a drug delivery system. Background Art

[0002] Inflammatory bowel disease has seriously affected the quality of life and daily life of patients. Currently, there are more than 3 million patients with inflammatory bowel disease in Europe and the United States. Most patients are diagnosed with the disease early in life, and the incidence rate is still rising. According to previous studies, the symptoms of inflammatory bowel disease are closely related to intestinal oxidative stress, intestinal flora imbalance and high expression of pro-inflammatory cytokines. Conventional treatments currently used in clinical practice, such as traditional chemotherapy drugs and anti-TNF-α monoclonal antibodies, have many adverse reactions in long-term treatment, and it is urgent to develop new and effective therapies to meet existing challenges.

[0003] With the rapid development of gene editing technology, CRISPR-Cas9 technology has become one of the most efficient, simplest and lowest-cost technologies in existing gene editing and gene modification. In this technology, Cas9 protein, with the help of guide RNA (sgRNA), specifically recognizes and cuts the complementary DNA sequence to achieve precise editing of the genome of the organism. Cas9 / sgRNA can be delivered to the cell in three forms: CRISPR-Cas9 plasmid, Cas9 mRNA and sgRNA, and ribonucleoprotein (RNP) complex of Cas9 protein and sgRNA. Among them, the RNP complex can be delivered to the cell nucleus through nuclear localization signals, and genome editing can be performed once it enters the cell. Therefore, RNP complex transduction has the fastest kinetic form in genome editing. As for the delivery vector of Cas9 / sgRNA, viral vectors have long been the most effective way to deliver host cells, but they have limitations such as immunogenicity and hepatotoxicity. Therefore, people have shifted their attention from viral delivery vectors to non-viral delivery vectors, such as cationic liposomes, liposome nanoparticles and exosomes. However, the effective and precise delivery of larger RNP complexes in vivo remains a challenge. Summary of the invention

[0004] In order to solve the above challenges, the purpose of the present invention is to design and construct an oral micro-nano CRISPR / Cas9 editing system, that is, a double-layer coated CRISPR / Cas9 editing system, to perform oral delivery of Cas9 / sgRNA RNP for the treatment of inflammatory bowel disease. TNF-α gene site-specific sgRNA is used to bind to Cas9 protein to form Cas9 / sgRNA RNP, which is cross-linked using a disulfide crosslinker bis(2,5-dioxopyrrolidine-1-yl)(dithiodiylbis(ethane-2,1-diyl)) dicarbonate to form RNP nanoclusters (RNP-NCs); bacterial outer membrane vesicles (dOMVs) from Escherichia coli Nissle 1917 (EcN) that have been depleted of lipopolysaccharide are extracted to initially coat RNP-NCs, and calcium alginate is coated on the outer layer to prepare calcium alginate microspheres (CAMs). The micro-nano CRISPR / Cas9 editing system constructed by the present invention can protect the contents from gastric acid erosion after oral administration, so that it can be targeted to the colon tissue in a complete drug form. After entering the colon tissue, the CAMs swell and rupture, releasing the contents; the dOMVs derived from the probiotic EcN are loaded with RNP-NCs and adhere to the deep intestinal mucosa, reshaping the intestinal microenvironment by improving the richness and diversity of the intestinal microbiota. Due to the excessive production of reactive oxygen species (radical oxygen species, ROS) in inflammatory cells, after RNP-NCs enter the cells, the disulfide crosslinker undergoes oxidation-responsive release, releasing the RNP, and entering the nucleus for site-specific gene editing. The present invention provides a new solution strategy for the oral delivery of Cas9 / sgRNA RNP, which will provide a scientific basis for the gene therapy of inflammatory bowel disease and has important research value.

[0005] The present invention achieves the above object through the following technical solutions:

[0006] The present invention provides a CRISPR / Cas9 editing system, which is a double-layer coated core-shell structure, wherein the inner core is a nanocluster RNP-NCs containing TNF-α gene site-specific sgRNA and Cas9 protein, and the outer shell is a nanoscale bacterial outer membrane vesicle dOMVs coating layer secreted by Escherichia coli E. coli Nissle 1917 and a micron-scale calcium alginate microsphere coating layer from the inside to the outside.

[0007] Based on the above technical solution, further, the nanocluster RNP-NCs are formed by cross-linking Cas9 / sgRNA RNP formed by the combination of sgRNA and Cas9 protein through a disulfide cross-linking agent, the molar ratio of sgRNA to Cas9 protein is 1:0.1-10, and the molar ratio of Cas9 / sgRNA RNP to the disulfide cross-linking agent is 1:5-20.

[0008] Based on the above technical solution, further, the nucleotide sequence of the sgRNA is 5'-UGGGCCAUAGAACUGAUGAGGUUUUAGAGCUAGAAAUAGCAAGUUA AAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU-3'.

[0009] Based on the above technical solution, further, the disulfide cross-linking agent includes bis(2,5-dioxopyrrolidine-1-yl)(dithiodiylbis(ethane-2,1-diyl))dicarbonate.

[0010] Based on the above technical solution, further, the dOMVs coating layer is formed by coating the nanocluster RNP-NCs with bacterial outer membrane vesicles secreted by Escherichia coli Nissle1917 and removing lipopolysaccharide; the protein content ratio of the nanocluster RNP-NCs to dOMVs is 1:0.2-5.

[0011] Based on the above technical solution, further, the calcium alginate microsphere coating layer is formed by gelling reaction of sodium alginate solution and calcium chloride solution on the outer surface of the dOMVs coating layer.

[0012] On the other hand, the present invention provides a method for constructing the above-mentioned CRISPR / Cas9 editing system, comprising the following steps:

[0013] (1) Cas9 and sgRNA were added to deionized water and mixed at room temperature to form a Cas9 / sgRNA RNP complex. The disulfide crosslinker was dissolved in an organic solvent and added to the Cas9 / sgRNA RNP complex. Uniform nanocluster RNP-NCs were spontaneously formed under stirring at room temperature.

[0014] (2) The E. coli Nissle 1917 bacterial solution was centrifuged to obtain a precipitate, the precipitate was resuspended in a phosphate buffer, ultrasonically disrupted, and the precipitate was retained after centrifugation. The precipitate was resuspended in a Tris buffer, the precipitate was removed by high-speed centrifugation, and then ultracentrifuged. The precipitate obtained was dOMVs;

[0015] (3) The nanocluster RNP-NCs and dOMVs were mixed evenly in deionized water, and the free RNP-NCs were removed by physical extrusion through a polycarbonate filter membrane with decreasing pore sizes to obtain RNP-NCs@dOMV;

[0016] (4) RNP-NCs@dOMV and 1-3% sodium alginate solution were mixed in equal volumes and injected into 1-3% calcium chloride solution under the extrusion of a high-speed syringe pump to obtain RNP-NCs@dOMV@CAM.

[0017] Based on the above technical solution, further, in step (1), the molar ratio of the sgRNA to the Cas9 protein is 1:0.1-10, and the concentration of Cas9 is 0.5-2 nmol / mL.

[0018] Based on the above technical solution, further, the organic solvent described in step (1) includes methanol, ethanol, dimethyl sulfoxide, acetone, dimethylformamide and dichloromethane.

[0019] Based on the above technical scheme, further, the molar ratio of Cas9 / sgRNA RNP to the disulfide crosslinker described in step (1) is 1:5-20; the disulfide crosslinker includes bis(2,5-dioxopyrrolidine-1-yl)(dithiodiylbis(ethane-2,1-diyl)) dicarbonate.

[0020] Based on the above technical solution, further, the Escherichia coli E. coli Nissle 1917 described in step (2) is cultured using LB medium.

[0021] Based on the above technical solution, further, the centrifugal condition in step (2) is 5000-7000×g for 10-30 minutes.

[0022] Based on the above technical solution, further, the volume of the phosphate buffer described in step (2) is 2 to 10 times the wet weight of the bacteria.

[0023] Based on the above technical solution, further, the volume of the Tris buffer in step (2) is 5 to 15 times the wet weight of the precipitate.

[0024] Based on the above technical solution, further, the high-speed centrifugation conditions described in step (2) are 10,000-15,000×g for 0.5-5 hours, and the ultracentrifugation conditions are 100,000-300,000×g for 0.5-5 hours.

[0025] Based on the above technical solution, further, the protein content ratio of the nanocluster RNP-NCs to dOMVs in step (3) is 1:0.2-5, and the protein concentration of the nanocluster RNP-NCs is 0.1-2.5 μg / mL.

[0026] Based on the above technical solution, further, in step (3), the pore sizes of the polycarbonate filter membrane are 1 μm, 400 nm, and 200 nm, respectively, and each pore undergoes 5 to 15 times of physical extrusion.

[0027] Based on the above technical solution, further, the protein concentration of the RNP-NCs@dOMV described in step (4) is 0.5-3 μg / mL;

[0028] On the other hand, the present invention provides the use of the above-mentioned CRISPR / Cas9 editing system in a drug delivery system.

[0029] On the other hand, the present invention provides the use of the above-mentioned CRISPR / Cas9 editing system in the preparation of anti-inflammatory drugs.

[0030] On the other hand, the present invention provides the use of the above-mentioned CRISPR / Cas9 editing system in the preparation of an injectable, oral or local drug delivery system.

[0031] The beneficial effects of the present invention compared with the prior art are as follows:

[0032] After oral administration of the micro-nano CRISPR / Cas9 editing system constructed by the present invention, the outermost CAMs can protect the contents from gastric acid erosion, allowing it to be targeted to the colon tissue in a complete drug form. After entering the colon tissue, the CAMs swell and rupture, releasing the contents; the dOMVs derived from the probiotic EcN are loaded with RNP-NCs and adhere to the deep intestinal mucosa, reshaping the intestinal microenvironment by improving the richness and diversity of the intestinal microbiota. Due to the excessive production of reactive oxygen species (radicaloxygen species, ROS) in inflammatory cells, after RNP-NCs enter the cells, the disulfide crosslinker undergoes oxidation-responsive release, releasing the RNP, and entering the nucleus for site-specific gene editing. The present invention provides a new solution strategy for the oral delivery of Cas9 / sgRNA RNP, which will provide a scientific basis for the gene therapy of inflammatory bowel disease and has important research value. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 This is a particle size distribution diagram of the nanocluster RNP-NCs in Example 1 of the present invention.

[0034] Figure 2 This is a transmission electron microscope image of the nanocluster RNP-NCs in Example 1 of the present invention.

[0035] Figure 3 This is a particle size distribution diagram of bacterial outer membrane vesicles dOMVs in Example 2 of the present invention.

[0036] Figure 4 This is an electron microscope image of the bacterial outer membrane vesicles dOMVs in Example 2 of the present invention.

[0037] Figure 5 This is the particle size distribution diagram of RNP-NCs@dOMV in Example 3 of the present invention.

[0038] Figure 6 This is a transmission electron microscopy image of RNP-NCs@dOMV in Example 3 of the present invention.

[0039] Figure 7 This is the potential diagram of RNP-NCs@dOMV in Example 3 of the present invention.

[0040] Figure 8 This is a fluorescence co-localization image of RNP-NCs@dOMV in Example 3 of the present invention.

[0041] Fig. 9 This is the particle size distribution diagram of RNP-NCs@dOMV@CAM in Example 4 of the present invention.

[0042] Fig.10 This is a confocal laser scanning image of RNP-NCs@dOMV@CAM in Example 4 of the present invention.

[0043] Fig.11 This is a graph showing the oxidation responsive release curve of RNP-NCs in Example 5 of the present invention.

[0044] Fig.12 This is a cumulative release curve of RNP-NCs@dOMV@CAM in Example 6 of the present invention in simulated gastric fluid and simulated intestinal fluid.

[0045] Fig.13 This is the cellular uptake of RNP-NCs@dOMV in Example 7 of the present invention.

[0046] Fig.14 This is the biocompatibility of RNP-NCs@dOMV in Example 8 of the present invention.

[0047] Fig.15 It is the gene editing efficiency of RNP-NCs@dOMV in Example 9 of the present invention.

[0048] Fig.16 This is the secretion of TNF-α after the cells were administered RNP-NCs@dOMV in Example 10 of the present invention.

[0049] Fig.17 This is the colon tissue distribution diagram of RNP-NCs@dOMV@CAM after oral gavage in Example 11 of the present invention.

[0050] Fig.18 This is a statistical graph of colon fluorescence after oral gavage of RNP-NCs@dOMV@CAM in Example 11 of the present invention.

[0051] Fig.19 This is a diagram of mouse colon tissue after oral gavage of RNP-NCs@dOMV@CAM in Example 12 of the present invention, wherein G1: Normal, G2: DSS, G3: DSS+5-ASA, G4: DSS+dOMVs, G5: DSS+RNP-NCs@dOMV, G6: DSS+RNP-NCs@dOMV@CAM.

[0052] Fig. 20 This is a statistical graph of the colon length of mice after oral gavage of RNP-NCs@dOMV@CAM in Example 12 of the present invention, wherein G1: Normal, G2: DSS, G3: DSS+5-ASA, G4: DSS+dOMVs, G5: DSS+RNP-NCs@dOMV, G6: DSS+RNP-NCs@dOMV@CAM.

[0053] Fig.21 This is a statistical chart of the weight changes of mice after oral gavage of RNP-NCs@dOMV@CAM in Example 12 of the present invention, where G1: Normal, G2: DSS, G3: DSS+5-ASA, G4: DSS+dOMVs, G5: DSS+RNP-NCs@dOMV, G6: DSS+RNP-NCs@dOMV@CAM.

[0054] Fig. 22 This is a graph of gene editing efficiency in mouse colon after oral gavage of RNP-NCs@dOMV@CAM in Example 12 of the present invention, wherein G1: Normal, G2: DSS, G3: DSS+5-ASA, G4: DSS+dOMVs, G5: DSS+RNP-NCs@dOMV, G6: DSS+RNP-NCs@dOMV@CAM.

[0055] Fig.23This is the H&E image of the mouse colon tissue after oral gavage of RNP-NCs@dOMV@CAM in Example 12 of the present invention, wherein G1: Normal, G2: DSS, G3: DSS+5-ASA, G4: DSS+dOMVs, G5: DSS+RNP-NCs@dOMV, G6: DSS+RNP-NCs@dOMV@CAM.

[0056] Fig.24 This is a statistical chart of cytokine and mRNA expression in mice after oral gavage of RNP-NCs@dOMV@CAM in Example 12 of the present invention, where G1: Normal, G2: DSS, G3: DSS+5-ASA, G4: DSS+dOMVs, G5: DSS+RNP-NCs@dOMV, G6: DSS+RNP-NCs@dOMV@CAM.

[0057] Fig.25 This is a statistical chart of the liver and kidney function indicators of mice after oral gavage of RNP-NCs@dOMV@CAM in Example 12 of the present invention, where G1: Normal, G2: DSS, G3: DSS+5-ASA, G4: DSS+dOMVs, G5: DSS+RNP-NCs@dOMV, G6: DSS+RNP-NCs@dOMV@CAM.

[0058] Fig.26 These are H&E images of the main organs (heart, liver, spleen, lung and kidney) of mice after oral gavage of RNP-NCs@dOMV@CAM in Example 12 of the present invention, where G1: Normal, G2: DSS, G3: DSS+5-ASA, G4: DSS+dOMVs, G5: DSS+RNP-NCs@dOMV, G6: DSS+RNP-NCs@dOMV@CAM. DETAILED DESCRIPTION

[0059] The above contents of the present invention are further described in detail through the following specific examples, but the examples do not limit the present invention.

[0060] Example 1: Construction and confirmation of nanocluster RNP-NCs

[0061] Cas9 protein (Edette (Shanghai) Biotechnology Co., Ltd.) and sgRNA (nucleotide sequence 5'-UGGGCCAUAGAACUGAUGAGGUUUUAGAGCUAGAAA UAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCA CCGAGUCGGUGCUUUU-3') at a molar ratio of 1:1 were mixed in deionized water (concentration of 1 nmol / mL), incubated for 15 min at room temperature, and the two formed a ribonucleoprotein complex RNP. A certain amount of disulfide crosslinker bis(2,5-dioxopyrrolidine-1-yl)(dithiodiylbis(ethane-2,1-diyl)) dicarbonate was dissolved in 10 μL DMSO and added to the above ribonucleoprotein complex RNP. The molar ratio of RNP to disulfide crosslinker was 1:10. After stirring at room temperature, nanocluster RNP-NCs were formed.

[0062] The particle size diagram and transmission electron microscopy image of the prepared nanocluster RNP-NCs are shown in Figure 1 , 2 As shown, the particle size and transmission electron microscopy images proved that RNP-NCs were successfully constructed.

[0063] Example 2: Preparation and confirmation of bacterial outer membrane vesicles dOMVs

[0064] ① Cultivation of E. coli Nissle 1917: Weigh a certain amount of tryptone, yeast extract, sodium chloride and water in a ratio of 1:0.5:1:100 (the ratio of solid drugs to liquids follows the mass ratio: volume ratio) to prepare LB liquid culture medium. Take 100μL of E. coli Nissle 1917 (provided by Shenyang Pharmaceutical University) bacterial solution and add it to 10mL LB culture medium. Cultivate it in a constant temperature shaking incubator at 37℃ overnight, transfer it to 1L LB liquid culture medium for expansion, and compare the blank with OD 600 =1.0 was taken as the culture end point and used for preparing bacterial stock solution.

[0065] ② Isolation and purification of dOMVs: The bacterial stock solution was centrifuged at 6000×g for 20 minutes at 4°C, and the pellet obtained by centrifugation was resuspended in 4 times the volume of phosphate buffer PBS (pH 7.4) of the wet weight, placed in an ice water bath and treated with 300W ultrasound for 30 minutes, then transferred to a 50mL centrifuge tube, centrifuged at 6000×g for 30 minutes at 4°C, and the pellet was retained. The pellet was resuspended in 0.1M Tris buffer (10×10 -3 M EDTA and 5 mg mL -1The volume of the buffer was 7.5 times the wet weight of the precipitate. Ultracentrifugation was performed at 12000×g for 1 hour at 4°C to remove cell debris. The supernatant was ultracentrifuged at 200000×g for 1 hour at 4°C to obtain the dOMVs precipitate, and washed again under the same conditions to finally obtain the purified dOMVs. The total protein content of dOMVs was determined using the BCA protein quantification kit and stored at -20°C for later use.

[0066] The particle size diagram and transmission electron microscopy image of the prepared dOMVs are shown in Figure 3 , 4 As shown, the particle size and transmission electron microscopy images proved that dOMVs were successfully prepared.

[0067] Example 3: Construction and confirmation of RNP-NCs@dOMV

[0068] RNP-NCs and dOMVs were mixed in deionized water at a protein content ratio of 1:1 (the protein concentration of RNP-NCs was 0.5 μg / mL) and then passed through polycarbonate filter membranes with pore sizes of 1 μm, 400 nm, and 200 nm in sequence by physical extrusion. Each pore size was physically extruded 10 times, and the free RNP-NCs were removed and concentrated using an Amicon Ultra15 centrifugal filter (100 kDa). RNP-NCs@dOMV were collected and placed in a 4°C refrigerator for later use.

[0069] RNP-NCs were prepared using the above method using Cas9 protein labeled with green fluorescent protein (GFP), and dOMVs were labeled with the lipophilic red fluorescent probe DiI (red, excitation wavelength / emission wavelength = 549 / 565nm). The extracted dOMVs (protein concentration of 0.5μg / mL) were mixed with DiI (5μmol / L) at a volume ratio of 1:1, incubated for 40 minutes, and ultracentrifuged at 200000×g for 1 hour to remove excess DiI dye. The treated GFP-RNP-NCs and DiI-dOMVs were passed through polycarbonate filters with pore sizes of 1μm, 400nm, and 200nm by physical extrusion, and each pore size was physically extruded 10 times. The co-localization of RNP-NCs and dOMVs was observed under a laser confocal scanning microscope.

[0070] The particle size, transmission electron microscopy, potential and fluorescence co-localization images of the prepared RNP-NCs@dOMV are shown in Figure 2. Figure 5-8 As shown, the particle size, transmission electron microscopy images, potential, and fluorescence co-localization images all proved that RNP-NCs@dOMV was successfully constructed.

[0071] Example 4: Construction and confirmation of RNP-NCs@dOMV@CAM

[0072] RNP-NCs@dOMV (protein concentration was 1 μg / mL) was mixed evenly with 2% sodium alginate solution in equal volumes and injected into 2% calcium chloride solution under the extrusion of a high-speed syringe pump. RNP-NCs@dOMV@CAM was collected and placed in a 4°C refrigerator for later use.

[0073] The particle size and confocal laser scanning images of the prepared RNP-NCs@dOMV@CAM are shown in Fig. 9 , 10 As shown, the particle size image and confocal laser scanning image both proved that RNP-NCs@dOMV@CAM was successfully constructed.

[0074] Example 5: Oxidation-responsive release behavior of RNP-NCs

[0075] Cas9 protein labeled with green fluorescent protein (GFP) was used to prepare RNP-NCs. RNP-NCs with a protein concentration of 0.5 μg / mL were dispersed in 1 mL of PBS (pH 7.4) and transferred to a dialysis bag with a molecular weight cutoff of 300 kDa. The dialysis bag was placed in a 50 mL centrifuge tube containing 10 mM or 100 mM hydrogen peroxide (H2O2), and the centrifuge tube was placed in a shaker for dialysis in the dark at 37 ° C and 100 rpm. 500 μL of the dialyzed external solution was taken out at 0, 1, 2, 4, 8, and 12 hours, and 500 μL of fresh 10 mM or 100 mM H2O2 PBS solution was added accordingly. The fluorescence intensity of the dialyzed external solution was measured at the excitation / emission wavelength (488 / 525 nm) using an enzyme marker.

[0076] The oxidation-responsive release curves of RNP-NCs are shown in Fig.11 As shown, the cumulative release curves indicated that RNP-NCs had an oxidation-responsive release behavior.

[0077] Example 6: Release behavior of RNP-NCs@dOMV@CAM in simulated gastric fluid and simulated intestinal fluid

[0078] RNP-NCs@dOMV and RNP-NCs@dOMV@CAM were prepared using GFP-tagged Cas9 protein. RNP-NCs@dOMV with a protein concentration of 1 μg / mL or RNP-NCs@dOMV@CAM containing the above concentration of RNP-NCs@dOMV were dispersed in 2 mL of PBS (pH 7.4) and transferred to a 50 mL centrifuge tube containing simulated gastric fluid (pH 1.2) or simulated intestinal fluid (pH 6.8). The tube was shaken at 37°C and 100 rpm in the dark. RNP-NCs@dOMV and RNP-NCs@dOMV@CAM were released in simulated gastric fluid (pH 1.2) for 4 hours before release. After 4 hours of release, the release medium was replaced with simulated intestinal fluid (pH 6.8) for subsequent release behavior investigation. Centrifuge at 4000 rpm at 0.5, 1, 2, 4, 6, 8, 10, 12, 18, 24, 30, and 36 hours, respectively, and take out 500 μL of supernatant. Add 500 μL of fresh medium to the centrifuge tube, and measure the fluorescence intensity of the supernatant after centrifugation at excitation / emission wavelengths (488 / 525 nm) using a microplate reader.

[0079] The cumulative release curves of RNP-NCs@dOMV and RNP-NCs@dOMV@CAM in simulated gastric fluid and simulated intestinal fluid are shown in Figure 2. Fig.12 As shown, the cumulative release curve indicated that RNP-NCs@dOMV@CAM was released only in a small amount in simulated gastric fluid and in a large amount in simulated intestinal fluid.

[0080] Example 7: Cellular uptake of RNP-NCs@dOMV

[0081] Laser confocal microscopy was used to investigate the time-dependent uptake of RNP-NCs@dOMV by macrophages RAW264.7. RNP-NCs@dOMV was prepared using GFP-tagged Cas9 protein. 5 RAW264.7 cells were seeded in 12-well plates and cultured in a cell culture incubator for 24 hours. The old culture medium was aspirated, and DMEM medium containing fluorescently labeled RNP-NCs@dOMV was added and incubated in a cell culture incubator for 2, 4, and 8 hours. After the incubation was terminated, the drug-containing culture medium was discarded and washed twice with preheated PBS (pH 7.4). 2μg / mL DiD working solution was prepared to treat the cells for 20 minutes to label the macrophage membrane, 4% paraformaldehyde was added to fix the cells, and DAPI was used to treat the cell nucleus for 10 minutes.

[0082] Cellular uptake of RNP-NCs@dOMV Fig.13 As shown, the cellular uptake of RNP-NCs@dOMV was time-dependent.

[0083] Example 8: Biocompatibility of RNP-NCs@dOMV

[0084] The biocompatibility of RNP-NCs@dOMV on macrophages RAW264.7 and colon cancer cell line CT26 was investigated. RAW264.7 cells or CT26 cells (1×10 4 / well) and cultured in a cell culture incubator for 24 hours to allow the cells to attach and grow. Subsequently, the culture medium was aspirated using a pipette, and a culture medium containing RNP-NCs@dOMV (equivalent to a total membrane protein concentration of 5, 10, 20, 40 μg / mL) was added and placed in a cell culture incubator for incubation for 24 hours. After the incubation, the old culture medium was aspirated, the cells were washed twice with preheated PBS buffer, and a culture medium containing 0.5 mg / mL of MTT was added to each well, and the cells were placed in an incubator for further incubation for 4 hours. The cell supernatant was discarded, DMSO (150 μL / well) was added and shaken for 10 minutes, and the absorbance value of each well was measured at a wavelength of 490 nm using a multifunctional microplate reader.

[0085] The biocompatibility of RNP-NCs@dOMV is shown in Fig.14 As shown, it indicates that RNP-NCs@dOMV has good biocompatibility for both cells.

[0086] Example 9: Gene Editing Efficiency of RNP-NCs@dOMV

[0087] 50 μL Opti-MEM medium, 36 pmol Cas9 protein, and 36 pmol sgRNA were incubated at room temperature for 15 min to construct the RNP complex. The RNP complex was mixed with 1.5 μL Lipo2000 and incubated at room temperature for 10 min as the Lipo2000 group; RNP-NCs (the amount of Cas9 protein and sgRNA was the same as that of the Lipo2000 group) were extruded with dOMVs with equal protein content ratios to prepare RNP-NCs@dOMV as the RNP-NCs@dOMV group. RAW264.7 cells (1×10 5 / well), cultured in a 37°C cell culture incubator for 24 hours to allow the cells to attach and grow. A macrophage inflammatory model was constructed by giving RAW264.7 cells 1 μg / mL of LPS and incubating them in a constant temperature cell culture incubator for 12 hours. The old cell culture medium was discarded, and fresh culture medium containing the Lipo2000 group and the RNP-NCs@dOMV group was added, respectively, and placed in a constant temperature cell culture incubator for 12 hours and replaced with fresh culture medium, and then incubated for another 24 hours. After the incubation, the cells were collected and genomic DNA was extracted using a cell DNA extraction kit. PCR amplification and T7EI enzyme digestion reactions were performed using the corresponding kits, and the products of T7EI enzyme digestion were subjected to 1% agarose gel electrophoresis, photographed and observed, and the enzyme digestion effect was analyzed. The gel bands photographed by the gel imaging system were analyzed using ImageJ software, and the indel percentage was used to evaluate the cutting efficiency of sgRNA.

[0088] The gene editing efficiency of RNP-NCs@dOMV is as follows Fig.15 As shown, RNP-NCs@dOMV had an indel efficiency of 16.7%.

[0089] Example 10: Evaluation of Inflammatory Indicators

[0090] RAW264.7 cells (1×10 5 / well), and cultured in a 37°C cell culture incubator for 24 hours to allow the cells to attach and grow. A macrophage inflammatory model was constructed by giving RAW264.7 cells 1 μg / mL of LPS and incubating them in a constant temperature cell culture incubator for 12 hours. The old cell culture medium was discarded, and fresh culture medium containing the Lipo2000 group and the RNP-NCs@dOMV group was added, respectively, and placed in a constant temperature cell culture incubator for 12 hours and replaced with fresh culture medium, and then incubated for another 24 hours. After the incubation, the cell supernatant was collected for the measurement of TNF-α expression.

[0091] The secretion of TNF-α in RAW264.7 cells after administration of RNP-NCs@dOMV Fig.16 As shown, it indicates that RNP-NCs@dOMV can reduce TNF-α expression.

[0092] Example 11: Evaluation of colon tissue distribution of RNP-NCs@dOMV@CAM after oral gavage

[0093] IBD mice induced by 3% DSS solution were used as the animal model for tissue distribution experiments. After modeling, the mice were randomly divided into four groups: 1) DSS+RNP-NCs; 2) DSS+RNP-NCs@dOMV; 3) DSS+RNP-NCs@dOMV@CAM; 4) Normal+RNP-NCs@dOMV@CAM. There were 12 mice in each group. Cas9 protein was labeled with Cy7-NHS, and Cy7-labeled RNP-NCs, RNP-NCs@dOMV and RNP-NCs@dOMV@CAM (labeled with Cy7, Cy7@dOMV and Cy7@dOMV@CAM, respectively) were prepared according to the above method. The three drugs were given by gavage at a concentration equivalent to 20 μg of Cas9 protein per mouse. The mice were killed and dissected 2, 4, 6 and 12 hours after gavage, and the intestines, heart, liver, spleen, lungs and kidneys were removed and imaged using the IVIS system, and the colon was quantified by fluorescence.

[0094] The colon tissue distribution of RNP-NCs@dOMV@CAM after oral gavage and the colon fluorescence statistics are shown in Fig.17 , 18 As shown, this indicates that RNP-NCs@dOMV has good colon retention ability.

[0095] Example 12: In vivo anti-inflammatory effect and safety evaluation of RNP-NCs@dOMV@CAM after oral administration

[0096] The mice without modeling were the Normal group, and the mice with successful colitis modeling were randomly divided into 5 groups. The dosing regimen was as follows: Group G1: Normal group, fed with pure water; Group G2: DSS group, given PBS gavage treatment; Group G3: DSS+5-ASA group, each mouse was given 150mg / kg 5-ASA by gavage every day; Group G4: DSS+dOMVs group, each mouse was given 5mgdOMVs every other day; Group G5: DSS+RNP-NCs@dOMV group, each mouse was given RNP-NCs@dOMV (equivalent to 20μg Cas9) every other day; Group G6: DSS+RNP-NCs@dOMV@CAM group, each mouse was given RNP-NCs@dOMV@CAM (equivalent to 20μg Cas9) every other day. Among them, the mice in the remaining groups were given the corresponding drugs, and oral gavage was given every other day for a total of three times, during which they were free to drink water. The weight changes of mice in each group were recorded daily, and the mice were killed by cervical dislocation on the 14th day. The serum, major organs (heart, liver, spleen, lung, kidney) and colon tissues of the killed mice were collected for blood analysis, T7EI enzyme digestion reaction and tissue H&E staining. The main indicators of investigation were: mouse colon length, mouse weight changes, in vivo gene editing efficiency, colon tissue pathology, cytokine and mRNA level detection, pathological changes of each tissue section and liver and kidney function indicators. The anti-inflammatory pharmacology and safety of RNP-NCs@dOMV@CAM were comprehensively evaluated.

[0097] Figure 2. Mouse colon tissue, colon length statistics, weight change statistics, colon gene editing efficiency, colon tissue H&E staining, in vivo cytokine and mRNA expression, liver and kidney function indicators, and H&E staining results of major organs after oral gavage of RNP-NCs@dOMV@CAM. Figure 19-26 As shown, the results showed that compared with simple dOMVs and RNP-NCs@dOMV, RNP-NCs@dOMV@CAM can exert very excellent anti-inflammatory effects after oral administration, and there are no significant safety risks.

Claims

1. A CRISPR / Cas9 editing system, characterized in that: The CRISPR / Cas9 editing system is a double-layer coated core-shell structure, the inner core is a nanocluster RNP-NCs containing TNF-α gene site-specific sgRNA and Cas9 protein, and the outer shell is composed of a nanoscale bacterial outer membrane vesicle dOMVs coating layer secreted by Escherichia coli E. coli Nissle 1917 and a micron-scale calcium alginate microsphere coating layer from the inside to the outside.

2. The CRISPR / Cas9 editing system according to claim 1, characterized in that The nanocluster RNP-NCs are formed by cross-linking Cas9 / sgRNA RNP formed by the combination of sgRNA and Cas9 protein through a disulfide crosslinker, the molar ratio of sgRNA to Cas9 protein is 1:0.1-10, and the molar ratio of Cas9 / sgRNA RNP to the disulfide crosslinker is 1:5-20; the nucleotide sequence of the sgRNA is 5'-UGGGCCAUAGAACUGAUGAGGUUUUAGAGCUAGAAAUAGCAAGUUA AAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGU GCUUUU-3'.

3. The CRISPR / Cas9 editing system according to claim 1, characterized in that The dOMVs coating layer is formed by coating the nanocluster RNP-NCs with the bacterial outer membrane vesicles secreted by Escherichia coli E.coli Nissle 1917 and removing lipopolysaccharide; the protein content ratio of the nanocluster RNP-NCs to the dOMVs is 1:0.2-5; the calcium alginate microsphere coating layer is formed by gelling reaction of sodium alginate solution and calcium chloride solution on the outer surface of the dOMVs coating layer.

4. The method for constructing the CRISPR / Cas9 editing system according to any one of claims 1 to 3, characterized in that: The steps include: (1) Cas9 and sgRNA were added to deionized water and mixed at room temperature to form a Cas9 / sgRNA RNP complex. The disulfide crosslinker was dissolved in an organic solvent and added to the Cas9 / sgRNA RNP complex. Uniform nanocluster RNP-NCs were spontaneously formed under stirring at room temperature. (2) The E. coli Nissle 1917 bacterial solution was centrifuged to obtain a precipitate, the precipitate was resuspended in a phosphate buffer, ultrasonically disrupted, and the precipitate was retained after centrifugation. The precipitate was resuspended in a Tris buffer, the precipitate was removed by high-speed centrifugation, and then ultracentrifuged. The precipitate obtained was dOMVs; (3) The nanocluster RNP-NCs and dOMVs were mixed evenly in deionized water, and the free RNP-NCs were removed by physical extrusion through a polycarbonate filter membrane with decreasing pore sizes to obtain RNP-NCs@dOMV; (4) RNP-NCs@dOMV and 1-3% sodium alginate solution were mixed in equal volumes and injected into 1-3% calcium chloride solution under the extrusion of a high-speed syringe pump to obtain RNP-NCs@dOMV@CAM.

5. The construction method according to claim 4, characterized in that: The molar ratio of the sgRNA to the Cas9 protein in step (1) is 1:0.1-10, and the concentration of Cas9 is 0.5-2 nmol / mL; the molar ratio of the Cas9 / sgRNA RNP to the disulfide crosslinker is 1:5-20; the disulfide crosslinker includes bis(2,5-dioxopyrrolidine-1-yl)(dithiodiylbis(ethane-2,1-diyl)) dicarbonate.

6. The construction method according to claim 4, characterized in that: The centrifugation conditions in step (2) are 5000-7000×g for 10-30 minutes; the volume of the phosphate buffer is 2-10 times the wet weight of the bacteria; the volume of the Tris buffer is 5-15 times the wet weight of the precipitate; the high-speed centrifugation conditions are 10000-15000×g for 0.5-5 hours, and the ultracentrifugation conditions are 100000-300000×g for 0.5-5 hours.

7. The construction method according to claim 4, characterized in that: The protein content ratio of the nanocluster RNP-NCs to dOMVs described in step (3) is 1:0.2~5, and the protein concentration of the nanocluster RNP-NCs is 0.1~2.5μg / mL; the pore sizes of the polycarbonate filter membrane are 1μm, 400nm, and 200nm, respectively, and each pore undergoes 5~15 times of physical extrusion; the protein concentration of the RNP-NCs@dOMV described in step (4) is 0.5~3μg / mL.

8. Use of the CRISPR / Cas9 editing system according to any one of claims 1 to 3 in a drug delivery system.

9. Use of the CRISPR / Cas9 editing system according to any one of claims 1 to 3 in the preparation of anti-inflammatory drugs.

10. Use of the CRISPR / Cas9 editing system according to any one of claims 1 to 3 in the preparation of an injectable, oral or topical drug delivery system.